ASH 2015 Complete Coverage
Idelalisib in combination with bendamustine and rituximab is superior to bendamustine and rituximab alone.
In "ultra-high risk" patients with chronic lymphocytic leukemia (CLL), treatment with venetoclax monotherapy resulted in a high overall response rate.
Results of a phase 3 randomized trial support high intensity conditioning prior to allogeneic stem cell transplantation as standard of care.
The first clinical trial of an anti-B-cell maturation antigen chimeric antigen receptor (CAR-BCMA) has shown strong anti-myeloma activity.
Minimal residual response (MRD) induced by blinatumomab montherapy was associated with longer survival and duration of response.
Adding ixazomib to lenalidomide plus dexamethasone in patients with relapsed/refractory multiple myeloma increased progression-free survival.
Ibrutinib is superior to temsirolimus for progression-free survival in patients with relapsed/refractory mantle cell lymphoma (MCL).
Combination of brentuximab vedotin with bendamustin is effective in Hodgkin lymphoma and anaplastic large T-cell lymphoma (ALCL).
For prognosis of long-term outcomes in chronic myeloid leukemia (CML), the European Treatment and Outcomes Study (EUTOS) score is recommended.
Obinutuzumab monotherapy for 1 cycle followed by venetoclax and obinutuzumab in elderly patients with chronic lymphocytic leukemia (CLL).
brutinib monotherapy was superior to chlorambucil with regard to survival and hematologic improvement.
Thromboprophylaxis with dalteparin is associated with a non-significant decreased risk of venous thromboembolism (VTE).
KPT-8602 allows a prolonged frequent dosing schedule in animal models of chronic lymphocytic leukemia (CLL) and acute myeloid leukemia (AML).
Combination therapy of venetoclax with decitabine or azacitidine demonstrated tolerable safety in acute myeloid leukemia (AML).
Genetic and pharmacologic evidence point to splicing factor mutant leukemias as being "preferentially sensitive to splicing modulation in vivo."
Adding rituximab to the pediatric-inspired GRAALL protocol improved event-free survival in acute lymphoblastic leukemia.
The addition of midostaurin to standard chemotherapy significantly improved survival in acute myeloid leukemia (AML).
Single-agent clofarabine is inferior to standard therapy in older patients with newly diagnosed acute myeloid leukemia (AML).
Research has confirmed "the importance of genetically defined PD-1 mediated immune evasion in classical Hodgkin lymphomas."
Researchers have confirmed 2 clinically relevant minimal residual disease checkpoints in younger patients with acute myeloid leukemia (AML).
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Long-term Survival From Ipilimumab/Nivolumab Combination in Metastatic Melanoma
- Radiation Therapy Increases 5-year Rate of Cardiac Events in Small-cell Lung Cancer
- Questions Remain for First-line Treatment Selection and Sequencing in Advanced Melanoma
- Pazopanib: Where Does It Stand as Adjuvant Therapy in Localized RCC?
- Repeat T790M Testing Recommended for TKI-resistant Patients With NSCLC
- Lung Cancer Treatment in North America: Recent Advances and Future Promises
- Atezolizumab Maintains Clinical Benefit After 2 Years in Advanced NSCLC
- Luminespib May Be Effective in NSCLC With EGFR Exon 20 Insertion Mutation
- Pembrolizumab After Locally Ablative Therapy May Be Beneficial in Metastatic NSCLC
- Liquid Biopsies Detect Unknown Driver Mutations in Advanced NSCLC